<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112371</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 90011_4023_1</org_study_id>
    <nct_id>NCT01112371</nct_id>
  </id_info>
  <brief_title>Contractubex Treatment in Scars After Abdominal Caesarean Section</brief_title>
  <acronym>ConMex</acronym>
  <official_title>A Prospective, Single-center, Randomized, Parallel Group Trial to Investigate the Efficacy of Contractubex® Gel, Containing Extractum Cepae, Allantoin, and Heparin, in Scars After Abdominal Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of Contractubex® Gel, containing
      extractum cepae, allantoin and heparin, in the treatment of scars after abdominal Caesarean
      section compared to untreated scars after abdominal Caesarean section.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Appearance of the scars will be evaluated by use of the Patient and Observer Scar Assessment Scale [POSAS].</measure>
    <time_frame>Screening and 12 weeks</time_frame>
    <description>The scale consists of two numeric scales which need to be filled out by the observer and the patient, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appearance of the scars will be evaluated by use of the Patient and Observer Scar Assessment Scale [POSAS].</measure>
    <time_frame>Screening and 6 weeks</time_frame>
    <description>The scale consists of two numeric scales which need to be filled out by the observer and the patient, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Scars</condition>
  <arm_group>
    <arm_group_label>Contractubex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Contractubex</intervention_name>
    <description>Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.
Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in.</description>
    <arm_group_label>Contractubex</arm_group_label>
    <other_name>Other names have not been specified.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females having given birth via elective abdominal Caesarean section for the first time
             within the last 5 to 10 days who had their suture removed (removed at screening).

          -  Age: 18 years or older.

          -  The subject must be willing and must be able to complete the entire course of the
             trial and to comply with the trial instructions.

          -  Written informed consent has been obtained from the subject.

          -  Females using suitable contraceptions.

        Exclusion Criteria:

          -  Use of any inadmissible medication, e.g. systemic corticosteroids, systemic
             immunosuppressants (such as cytostatics, therapy with antibodies, biologics,
             interferone, mykophenolatmofetil, methotrexate, cyclosporine, azathioprine). Any
             additional topical treatment in the area of the lower abdomen, regardless of the mode
             of action.

          -  Any other planned topical treatment in the lower part of the abdomen during the course
             of the trial.

          -  Any infection or wound in the area to treat.

          -  History of keloids or hypertrophic scars.

          -  Any severe or uncontrolled systemic disease (e.g. cardiac, renal, pulmonary, hepatic,
             or gastrointestinal), malignant tumor, or medical history of HIV infection.

          -  Any tumor diseases in the abdominal region independent of their dignity.

          -  Females having given birth via emergency abdominal Caesarean section.

          -  Psychiatric problems which, in the investigator's opinion, are severe enough to
             interfere with the trial results.

          -  Participation in another clinical trial within 30 days prior to screening.

          -  Evidence or suspicion that the subject might not comply with the study directives
             and/or that she is not reliable or trustworthy.

          -  Evidence or suspicion that the subject is not willing or unable to understand the
             information given to her as part of the informed consent, in particular regarding the
             risks and discomfort to which she would agree to be exposed.

          -  Previous participation in this clinical study.

          -  Known allergy or hypersensitivity to the study drug(s) or one of the ingredients of
             the formulation.

          -  Subjects who are imprisoned or are lawfully kept in an institution.

          -  Employees or direct relatives of an employee of the CRO, the study center or Merz
             Pharmaceuticals.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Ocampo Candiani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jefe del Departamento Dermatologia, Facultad de medicina y Hospital Universitario, Universidad Autonoma de Nuevo León, Monterrey Nuevo León,C.P. 64460, Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jefe del Departamento Dermatologia, Facultad de medicina y Hospital Universitario, Universidad Autonoma de Nuevo León</name>
      <address>
        <city>Monterrey Nuevo León</city>
        <state>C.p.</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Ocampo-Candiani J, et al. Efficacy of a topical gel containing extractum cepae, allantoin and heparin in the treatment of abdominal caesarean section scars. IMCAS Annual Meeting 2013. www.imcas.com/en/imcas2013/schedule/lecture/id/5971</citation>
  </results_reference>
  <results_reference>
    <citation>Ocampo-Candiani J, Vázquez-Martínez OT, Iglesias Benavides JL, Buske K, Lehn A, Acker C. The prophylactic use of a topical scar gel containing extract of Allium cepae, allantoin, and heparin improves symptoms and appearance of cesarean-section scars compared with untreated scars. J Drugs Dermatol. 2014 Feb;13(2):176-82.</citation>
    <PMID>24509969</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>April 7, 2014</last_update_submitted>
  <last_update_submitted_qc>April 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>scars after abdominal Caesarean section</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allantoin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

